← Oncology Approval Tracker

FDA DECISION ·

Imfinzi

durvalumab · AstraZeneca

FDA approvalNew dosing regimenNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An alternative 1,500 mg every four weeks schedule for patients weighing at least 30 kg with unresectable stage III non-small cell lung cancer or the then-approved urothelial carcinoma indication.

LAMPGEN ANALYSIS

Why it matters

Offered a longer infusion interval for two existing indications; the U.S. urothelial carcinoma indication was later withdrawn.

What research teams should watch

Keep infusion schedules and labeled disease status distinct, and verify applicable weight-based dosing rules.

PRIMARY RECORDS

Sources